Research demonstrates enhanced solubility and stability of ivacaftor via crystal engineering in drug formulation.
Ivacaftor (IVA) is a selective small-molecule potentiator used to treat cystic fibrosis in patients with certain genetic mutations. It is a BCS class II drug having poor aqueous solubility. The...
No takes yet. Share an insight, caveat, or question.
Doguparthi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: